Dell Technologies Inc vs ResMed Inc. — how do they compare? Dell Technologies Inc trades at $455 (market cap $284.93B), while ResMed Inc. trades at $220 (market cap $32.61B). The key difference: Dell Technologies Inc is far larger — about 8.7× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.17%). Which is the better fit depends on your goals.
| DELL | RMD | |
|---|---|---|
Market Cap | $284.93B | $32.61B |
Sector | Technology | Health |
52-Week High | $467.27 | $293.73 |
52-Week Low | $111.10 | $182.82 |
Enterprise Value | $304.51B | $31.97B |
Dividend Yield | 0.57% | 1.17% |
Signals from Pluang's Aura AI — not financial advice
Dell Technologies stock trades at $457.93, up 0.92% on the day, near its 52-week high. Recent earnings beats, including Q1 2026 EPS of $4.86 versus $2.96 expected, highlight strong operational performance. The technical outlook is bullish with support at $448 and resistance at $471. Revenue for 2025 reached $95.57 billion with net income of $4.59 billion, though cash flow trends show net outflows.
The outlook remains positive driven by AI server demand and commercial PC refresh cycles, with a consensus price target of $503.76 implying 10% upside. Risks include valuation concerns at a P/E of 35.14 and competitive pressures in the tech hardware sector. Institutional sentiment is bullish with 57.78% of analysts rating Buy.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →